<?xml version='1.0' encoding='utf-8'?>
<document id="28550384"><sentence text="Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers."><entity charOffset="17-47" id="DDI-PubMed.28550384.s1.e0" text="Glycochenodeoxycholate Sulfate" /><entity charOffset="52-81" id="DDI-PubMed.28550384.s1.e1" text="Chenodeoxycholate Glucuronide" /><pair ddi="false" e1="DDI-PubMed.28550384.s1.e0" e2="DDI-PubMed.28550384.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28550384.s1.e0" e2="DDI-PubMed.28550384.s1.e1" /></sentence><sentence text="To assess the use of glycochenodeoxycholate-3-sulfate (GCDCA-S) and chenodeoxycholate 3- or 24-glucuronide (CDCA-3G or -24G) as surrogate endogenous substrates in the investigation of drug interactions involving OATP1B1 and OATP1B3"><entity charOffset="21-53" id="DDI-PubMed.28550384.s2.e0" text="glycochenodeoxycholate-3-sulfate" /><entity charOffset="55-62" id="DDI-PubMed.28550384.s2.e1" text="GCDCA-S" /><entity charOffset="68-106" id="DDI-PubMed.28550384.s2.e2" text="chenodeoxycholate 3- or 24-glucuronide" /><entity charOffset="108-115" id="DDI-PubMed.28550384.s2.e3" text="CDCA-3G" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e0" e2="DDI-PubMed.28550384.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e0" e2="DDI-PubMed.28550384.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e0" e2="DDI-PubMed.28550384.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e0" e2="DDI-PubMed.28550384.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e1" e2="DDI-PubMed.28550384.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e1" e2="DDI-PubMed.28550384.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e1" e2="DDI-PubMed.28550384.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e2" e2="DDI-PubMed.28550384.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28550384.s2.e2" e2="DDI-PubMed.28550384.s2.e3" /></sentence><sentence text="" /><sentence text="Uptake of GCDCA-S and CDCA-24G was examined in HEK293 cells transfected with cDNA for OATP1B1, OATP1B3, and NTCP and in cryopreserved human hepatocytes" /><sentence text=" Plasma concentrations of bile acids and their metabolites (GCDCA-S, CDCA-3G, and CDCA-24G) were determined by LC-MS/MS in eight healthy volunteers with or without administration of rifampicin (600Â mg, po)"><entity charOffset="26-36" id="DDI-PubMed.28550384.s5.e0" text="bile acids" /><entity charOffset="182-192" id="DDI-PubMed.28550384.s5.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.28550384.s5.e0" e2="DDI-PubMed.28550384.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28550384.s5.e0" e2="DDI-PubMed.28550384.s5.e1" /></sentence><sentence text="" /><sentence text="GCDCA-S and CDCA-24G were substrates for OATP1B1, OATP1B3, and NTCP" /><sentence text=" The uptake of [3H]atorvastatin, GCDCA-S, and CDCA-24G by human hepatocytes was significantly inhibited by both rifampicin and pioglitazone, whereas that of taurocholate was inhibited only by pioglitazone"><entity charOffset="15-31" id="DDI-PubMed.28550384.s8.e0" text="[3H]atorvastatin" /><entity charOffset="33-40" id="DDI-PubMed.28550384.s8.e1" text="GCDCA-S" /><entity charOffset="46-54" id="DDI-PubMed.28550384.s8.e2" text="CDCA-24G" /><entity charOffset="112-122" id="DDI-PubMed.28550384.s8.e3" text="rifampicin" /><entity charOffset="127-139" id="DDI-PubMed.28550384.s8.e4" text="pioglitazone" /><entity charOffset="157-169" id="DDI-PubMed.28550384.s8.e5" text="taurocholate" /><entity charOffset="192-204" id="DDI-PubMed.28550384.s8.e6" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e0" e2="DDI-PubMed.28550384.s8.e6" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e1" e2="DDI-PubMed.28550384.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e1" e2="DDI-PubMed.28550384.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e1" e2="DDI-PubMed.28550384.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e1" e2="DDI-PubMed.28550384.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e1" e2="DDI-PubMed.28550384.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e1" e2="DDI-PubMed.28550384.s8.e6" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e2" e2="DDI-PubMed.28550384.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e2" e2="DDI-PubMed.28550384.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e2" e2="DDI-PubMed.28550384.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e2" e2="DDI-PubMed.28550384.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e2" e2="DDI-PubMed.28550384.s8.e6" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e3" e2="DDI-PubMed.28550384.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e3" e2="DDI-PubMed.28550384.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e3" e2="DDI-PubMed.28550384.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e3" e2="DDI-PubMed.28550384.s8.e6" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e4" e2="DDI-PubMed.28550384.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e4" e2="DDI-PubMed.28550384.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e4" e2="DDI-PubMed.28550384.s8.e6" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e5" e2="DDI-PubMed.28550384.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28550384.s8.e5" e2="DDI-PubMed.28550384.s8.e6" /></sentence><sentence text=" Rifampicin elevated plasma concentrations of GCDCA-S more than those of other bile acids"><entity charOffset="1-11" id="DDI-PubMed.28550384.s9.e0" text="Rifampicin" /><entity charOffset="79-89" id="DDI-PubMed.28550384.s9.e1" text="bile acids" /><pair ddi="false" e1="DDI-PubMed.28550384.s9.e0" e2="DDI-PubMed.28550384.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28550384.s9.e0" e2="DDI-PubMed.28550384.s9.e1" /></sentence><sentence text=" The area under the plasma concentration-time curve for GCDCA-S was 20" /><sentence text="3 times higher in rifampicin-treated samples"><entity charOffset="18-28" id="DDI-PubMed.28550384.s11.e0" text="rifampicin" /></sentence><sentence text=" CDCA-24G could be detected only in plasma from the rifampicin-treatment phase, and CDCA-3G was undetectable in both phases"><entity charOffset="1-9" id="DDI-PubMed.28550384.s12.e0" text="CDCA-24G" /><entity charOffset="52-62" id="DDI-PubMed.28550384.s12.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.28550384.s12.e0" e2="DDI-PubMed.28550384.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28550384.s12.e0" e2="DDI-PubMed.28550384.s12.e1" /></sentence><sentence text="" /><sentence text="We identified GCDCA-S and CDCA-24G as substrates of NTCP, OATP1B1, and OATP1B3" /><sentence text=" GCDCA-S is a surrogate endogenous probe for the assessment of drug interactions involving hepatic OATP1B1 and OATP1B3" /><sentence text="" /></document>